oxidopamine has been researched along with adenine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bobalova, J; Lew, C; Mendoza, MG; Mutafova-Yambolieva, VN; Smyth, LM | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Batassini, C; Bogo, MR; Böhmer, AE; Bonan, CD; Mello e Souza, T; Oliveira, A; Oses, JP; Pochmann, D; Portela, LV; Sarkis, JJ; Silvestrin, RB; Souza, DO; Vuaden, FC | 1 |
| Arsikin, K; Harhaji-Trajkovic, L; Janjetovic, K; Kostic-Rajacic, S; Misirkic-Marjanovic, M; Schrattenholz, A; Soskic, V; Tovilovic, G; Trajkovic, V; Vucicevic, L; Zogovic, N | 1 |
| Borsini, F; Caprioli, A; Di Serio, S; Lombardo, K; Minetti, P; Pace, S; Riccioni, T; Stasi, MA; Vertechy, M | 1 |
| Axten, JM; Castillo, V; Hetz, C; Hoozemans, JJM; López, N; Mercado, G; Sardi, SP; Soto, P | 1 |
8 other study(ies) available for oxidopamine and adenine
| Article | Year |
|---|---|
Release of beta-nicotinamide adenine dinucleotide upon stimulation of postganglionic nerve terminals in blood vessels and urinary bladder.
Topics: Acetaldehyde; Adenine; Adenosine Triphosphate; Adrenergic Agents; Anesthetics, Local; Animals; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cyclic ADP-Ribose; Dogs; Electrochemistry; Electrophysiology; Female; Guanethidine; Guinea Pigs; Hydrogen-Ion Concentration; Male; Mesenteric Arteries; Mice; Models, Chemical; Muscle, Smooth; NAD; Norepinephrine; omega-Conotoxin GVIA; Oxidopamine; Rabbits; Rats; Rats, Wistar; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stress, Mechanical; Temperature; Tetrodotoxin; Time Factors; Urinary Bladder | 2004 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
The hydrolysis of striatal adenine- and guanine-based purines in a 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 5'-Nucleotidase; Acid Anhydride Hydrolases; Adenine; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Guanine; Isoenzymes; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Phosphates; Rats; Rats, Wistar | 2011 |
Arylpiperazine-mediated activation of Akt protects SH-SY5Y neuroblastoma cells from 6-hydroxydopamine-induced apoptotic and autophagic death.
Topics: Adenine; Adrenergic Agents; Analysis of Variance; Apoptosis; Autophagy; Cell Survival; Cytoplasm; Dose-Response Relationship, Drug; Drug Interactions; Humans; Macrolides; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Piperazines; Proto-Oncogene Proteins c-akt; Pyridines; RNA, Small Interfering; Signal Transduction; Superoxides; Time Factors | 2013 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Basal Ganglia; Binding, Competitive; Catalepsy; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; HEK293 Cells; Humans; Injections, Intraperitoneal; Ligands; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Transfection; Triazoles | 2015 |
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease.
Topics: Adenine; Animals; Disease Models, Animal; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |